A retrospective analysis found that only 42.0% and 18.9% of patients with high-risk and low-risk polycythemia vera, respectively, received cytoreductive therapy overall, despite guidelines recommending the treatment as part of risk-adapted therapy.
Experimental Hematology & Oncology